SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| SCHECHTER JONATHAN | Director | 2026-01-07 | Open-market buy | 20000 | $17K |
| Silverman Joshua | CEO and President, Director | 2026-01-07 | Open-market buy | 40000 | $33K |
| SCHECHTER JONATHAN | Director | 2026-01-06 | Open-market buy | 20000 | $16K |
| Silverman Joshua | CEO and President, Director | 2026-01-06 | Open-market buy | 30000 | $24K |
| SCHECHTER JONATHAN | Director | 2026-01-05 | Open-market buy | 20000 | $16K |
| Silverman Joshua | CEO and President, Director | 2026-01-05 | Open-market buy | 30000 | $23K |
| Abecassis Michael M | Director | 2025-12-12 | Grant/award | 37500 | $0 |
| Abecassis Michael M | Director | 2025-12-12 | Tax withholding | 16875 | $17K |
| SCHECHTER JONATHAN | Director | 2025-12-12 | Grant/award | 150000 | $0 |
| SCHECHTER JONATHAN | Director | 2025-12-12 | Tax withholding | 67500 | $69K |
| Silverman Joshua | CEO and President, Director | 2025-12-12 | Grant/award | 575000 | $0 |
| Silverman Joshua | CEO and President, Director | 2025-12-12 | Tax withholding | 258750 | $264K |
| WALKER WAYNE REMELL | Director | 2025-12-12 | Grant/award | 37500 | $0 |
| WALKER WAYNE REMELL | Director | 2025-12-12 | Tax withholding | 16875 | $17K |
| WEINSTEIN ROBERT | Director | 2025-12-12 | Grant/award | 75000 | $0 |
| WEINSTEIN ROBERT | Director | 2025-12-12 | Tax withholding | 33750 | $34K |
Fiscal period ending 2026-04-30 versus 2025-04-30 — view filing on EDGAR →
The company faces acute solvency and delisting risk: it is non-compliant with Nasdaq minimum bid price requirements, faces immediate suspension if MVLS falls below $5M, and swung from $23M net income to a $23M net loss while its accumulated deficit grew to $104M. A 5+ year unresolved FDA clinical hold with no timeline — now further threatened by FDA capacity constraints — eliminates near-term revenue visibility for a pre-revenue biotech entirely dependent on external financing. New Series C Preferred obligations, a sole-source Singapore manufacturer exposed to tariff and geopolitical risk, and concentrated asset exposure in Femasys and QCLS securities compound an already severely deteriorated risk profile.
9 company-specific · 1 eased/removed · 2 common-mode
Company is currently non-compliant with Nasdaq minimum bid price requirement and faces delisting risk. This materially threatens liquidity, capital-raising ability, and stock trading market access.
We are not currently in compliance with the continued listing requirements for Nasdaq, and if we are unable to regain compliance, our common stock could be delisted from Nasdaq or another nationally…
New Nasdaq delisting rule with immediate suspension risk if MVLS falls below $5M for 30 days. Company acknowledges MVLS may already be at or near threshold. Delisting would severely impair liquidity and capital-raising ability.
Nasdaq’s recently adopted minimum Market Value of Listed Securities requirement of $5 million could result in the suspension and delisting of our common stock from Nasdaq. On July 22, 2026, the SEC…
New $7M Series C Preferred issuance with senior liquidation preference, 7% dividend (15% on trigger), and redemption rights materially dilutes common equity and increases financial obligations.
Our outstanding Series C Convertible Preferred Stock has dividend, liquidation, redemption, anti-dilution and voting rights that are senior to, or could dilute, the rights of holders of our common…
New disclosure of material supply chain vulnerability: sole manufacturer in Singapore dependent on tariffs, trade policy, geopolitical stability. Identifies existing Austrianova liquidity concerns and manufacturing delays.
Changes in U.S. trade policy, tariffs, and geopolitical conditions could disrupt our supply chain, increase our costs, and materially harm our business. Our product candidates are manufactured…
Clinical hold now disclosed as persisting 5+ years with no resolution timeline, escalating severity and business viability risk materially.
As a result of the clinical hold that has been placed on our IND by the FDA, it has taken and may continue to take considerable time and expense to respond to the FDA and no assurance can be given…
New disclosure of material regulatory risk: FDA clinical hold on IND cannot be lifted if FDA capacity is impaired by shutdowns, staffing cuts, or funding reductions. Company's development timeline entirely dependent on FDA engagement.
U.S. government shutdowns, reductions in FDA staffing and funding, or other disruptions to FDA operations could further delay the lifting of the clinical hold on our IND and materially harm our…
Accumulated deficit increased from $85M to $104M; net loss of $23M in 2026 vs. prior year net income of $23M. Deteriorating financial position signals worsening liquidity risk.
Risks Related to Our Financial Position, FDA Clinical Hold, Need for Additional Capital and Overall Business We are a biotechnology company with limited resources, a limited operating history, and no…
Added specific AI-driven cyberattack risks, key-person dependency on contracted CISO, and insurance adequacy concerns—substantive escalations of threat sophistication and operational vulnerability.
We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our…
New disclosure of substantial asset concentration risk in Femasys and QCLS securities. Added explicit warning that adverse developments could materially affect financial condition.
We face risks related to owning securities issued by other public companies. We own securities of other public companies, the MyMD Pharmaceuticals Inc. which subsequently changed its name to TNF…
Removal of delisting risk disclosure suggests company now meets Nasdaq listing requirements, materially easing liquidity and financing concerns previously flagged.
We may not be able to meet the continued listing requirements for Nasdaq or another nationally recognized stock exchange, which could limit investors’ ability to make transactions in our securities…
New disclosure of material macro risks: inflation raising preclinical/clinical costs, rising rates reducing capital availability, tightening markets threatening equity financing for pre-revenue biotech dependent on external funding.
Adverse macroeconomic conditions, including inflation, rising interest rates, and tightening capital markets, could increase our operating costs and impair our ability to raise capital on acceptable…
New disclosure of competitive disadvantage from AI adoption lag, IP/data breach risk via employee AI use, and evolving regulatory compliance burden in healthcare AI.
Rapid advances in artificial intelligence by our competitors and third parties may place us at a competitive disadvantage, and the use of AI technologies by our employees, consultants, or service…
We track this company, but none of its filings have been classified as material yet. New filings land after EDGAR’s nightly publish (~10 PM ET).